In addition to the three commonly recognized classes of human immunoglobulins (IgG, IgA, and IgM), a fourth immunoglobulin class was recently identified and designated IgD (yD) (1, 2). Serum values in normal subjects ranged from less than 3 ug to greater than 100 /Ag IgD per ml of serum (2). The median serum IgD concentration was 30 Mg per ml, about 1/, o of the serum IgG concentration. IgD is the least plentiful member of the immunoglobulin family.
(From the Immunology Branch and Metabolism Service, National Cancer Institute, National
Institutes of Health, Bethesda, Md., and the Department of Experimental Pathology, The Medical School, University of Birmingham, Birmingham, England) In addition to the three commonly recognized classes of human immunoglobulins (IgG, IgA, and IgM), a fourth immunoglobulin class was recently identified and designated IgD (yD) (1, 2) . Serum values in normal subjects ranged from less than 3 ug to greater than 100 /Ag IgD per ml of serum (2) . The median serum IgD concentration was 30 Mg per ml, about 1/, o of the serum IgG concentration. IgD is the least plentiful member of the immunoglobulin family.
The immunoglobulin system is interesting from a metabolic standpoint. The biological half-life of normal IgG is about 23 days and its synthetic rate 40 mg per kg per day (3, 4) . In contrast, the half-lives of IgA and IgM are about the same (4 to 5 days), but the synthetic rate of 20 mg per kg per day for IgA compared to 4 mg per kg per day for IgM explains in part the higher serum level of IgA (5-7).
Nothing was known, however, about the metabolic behavior of immunoglobulin D. We therefore undertook this study using radioactive iodinelabeled IgD hoping to elucidate reasons for the relatively low serum concentration and to determine whether the metabolism of IgD is related to that of the other immunoglobulin classes.
The metabolism of labeled IgD was investigated in 28 patients selected so as to cover a wide range of immunoglobulin disorders. These included patients with a) increased synthesis of specific immunoglobulins, b) deficient immunoglobulin synthesis, c) increased catabolism of certain immunoglobulins, and d) no discernible abnormalities of the immunoglobulin system. The results of these studies indicate that the synthetic rate is the major factor controlling the serum IgD concen-Institute, Bethesda, Md. 20014. tration and that IgD is metabolized independently of the other immunoglobulins.
Methods
Preparation of labeled IgD. IgD was isolated from whole human serum or plasma by DEAE cellulose chromatography followed by Sephadex G-200 gel filtration according to the method of Rowe and Fahey (2) .
Two separate studies were done with radioiodinelabeled IgD. Different sources of IgD were used for each study; therefore, the preparation and characterization of the labeled purified proteins will be discussed separately.
IgD preparation no. 1. This protein was prepared from sterile frozen plasma obtained 1j years previously from a patient with an immunoglobulin deficiency syndrome (8) who had 0.6 mg per ml IgD of both Types K and L and abundant serum IgM, but only trace quantities of IgG and IgA. Thirty ml of plasma was applied to each of two 20-g DEAE cellulose columns at 240 C equilibrated with 0.01 M phosphate buffer, pH 8.0, with a gradient of phosphate buffer to 0.30 M final buffer. Effluent fractions were tested for presence of specific protein fractions by Ouchterlony analysis with specific anti-IgD, IgG, IgA, and IgM antisera prepared in rabbits (1, 9) , goat antihuman transferring and a horse antinormal human serum.
Effluent fractions containing IgD were pooled and ultrafiltered to about 2 ml, made 3% in sucrose, and applied to a Sephadex G-200 column equilibrated at 240 C with 0.2 M Tris buffer, pH 8.0, in 0.2 M NaCl. The effluent containing IgD was again identified and ultrafiltered to about 2 ml to yield IgD preparation no. 1 . Total protein content of this ultrafiltrate was 3.6 mg per ml as estimated from the OD at 280 mis, assuming an extinction coefficient of 13.5. Antibody-in-agar ring diffusion analysis (2, 10) revealed an IgD concentration of 4.1 mg per ml with a standard reference serum of IgD concentration 0.33 mg per ml.
Ouchterlony analysis of this concentrated preparation showed a heavy precipitin line with specific anti-IgD antisera. Transferrin was also detected and found to be 0.05 mg per ml with commercial antitransferrin agar plates,' i.e., about 1.3%o of the total protein was transferrin. Antisera specific to IgA and IgG failed to react with preparation no. 1. Anti-IgM antisera did yield a This radioiodinated protein was characterized by Sephadex gel filtration, radio-Ouchterlony analysis, and radioimmunoelectrophoresis. One-half ml (2.6 ,c) IgD-I was added to 3.0 ml of normal carrier serum and put on a Sephadex G-200 column (Figure 1 ). The radioactivity appeared as a single symmetrical peak midway between the first and second optical density peaks, the typical elution position for IgD (2 Table I . Eight patients had multiple myeloma. Of this group only one (A.J.) had never received either cytotoxic drugs or steroids. Six of the eight were receiving drugs during the study. Renal disease was evident in two patients, G.C. [proteinuria, 0.5 g per day; blood urea nitrogen (BUN), 30; creatinine clearance, 79 L per 24 hours] and F.M. (Bence Jones proteinuria, BUN of 25, hypercalcemia). Although patient B.M. had Bence Jones proteinuria (3.7 g per day), he had no other laboratory evidence of renal disease. Patient W.H. had a drop in hemoglobin of 2 g per 100 ml on the third day of the study due in part to gastrointestinal blood loss and also to a Coombs' positive hemolytic anemia. Oral potassium iodide was stopped because of possible gastric irritation, and 1,250 ml of packed red blood cells was transfused over the fourth and fifth days of the study. Patient F.M. received 500 ml of packed red blood cells on the second day of one turnover study (preparation no. 2-a).
Four patients had macroglobulinemia as confirmed by serum immunoelectrophoresis and ultracentrifugation. One, A.C., had, in addition, amyloidosis involving the peripheral nerves and renal disease of uncertain etiology with a creatinine clearance of 74 .L per 24 hours. All patients had received some form of chemotherapy in the past, but only two (K.I., H.Hi.) were on therapy during the major part of the study. Patient J.B. was treated with plasmapheresis before each study but not for 2 days before or during the study.
Four other patients with known abnormalities in immunoglobulin metabolism were included: P.B., congenital agammaglobulinemia, who was suffering from mild chronic bronchitis and bronchiectasis, but received no y-globulin during the study or during the 2 weeks before study; G.L., ataxia telangiectasia, with known decreased synthesis and increased catabolism of IgA (6); and W.J. and J.C., both with myotonic dystrophy and accelerated IgG catabolism (12) . J.C. had evidence of mild hepatic disease [mildly elevated serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), lactic dehydrogenase (LDH), and alkaline phosphatase].
Twelve patients with a variety of other diseases were studied. One (A.Ha.) had renal disease (BUN, 23; creatinine clearance, 94 L per 24 hours). Seven had cancer; six were receiving chemotherapy. One, A.W., developed parotitis on the fourth day of the study necessitating stopping potassium iodide. All patients were considered suitable for study. None was considered critically ill; only one (N.S.) had a fever of over 99.50 F during the study.
The transfusions (subjects W.H. and F.M.), gastrointestinal bleeding (subject W.H.), and the cessation of iodide administration (subjects W.H. and A.W.) did not change the respective plasma radioactivity curves (see below).
Study protocol and calculation of data. Each patient received 0.5 ml of Lugol's solution or a saturated solution of potassium iodide three times a day before and during the study. In two patients iodides were stopped during the study (see above). Approximately 15 to 35 ,uc (0.1 to 1.2 mg) of labeled IgD was injected intravenously from calibrated syringes. Plasma samples were obtained at 10 minutes after injection, several times during the first 24 hours, twice and then only once daily. Urine was collected in 24-hour pools throughout the study. In some patients, 24-hour lots of stool (days 1 through 4 of the study) were examined for radioactivity. Serum and urine samples were counted in an automatic gamma-ray well-type scintillation counter employing a thallium-activated sodium iodide crystal. For three patients (M.M., N.S., and B.M.) total body radioactivity was measured daily by whole body counters. Exhaustive dialysis or trichloroacetic acid precipitation of the urine samples revealed 4%, or less protein-bound radioactivity in all patients tested, even in those (B.M., F.M., G.C.) with proteinuria. Stools were collected in paint cans and homogenized. The sample cans brought to the same weight with water and appropriate standards were counted in a Tobor 2 large sample gamma counter. In each patient tested less than 0.25% of the injected radioactivity appeared in any 24-hour stool sample.
Plots were constructed on semilogarithmic paper of the plasma radioactivity and of the remaining total body activity as plotted against time. Total body activity was calculated by cumulative subtraction of radioactivity excreted in urine and stool from that originally administered or by the whole body counting technique. After initial equilibration the plasma curves for both preparations 1 and 2 declined as a single exponential function, each having a slope comparable to the total body curves ( Figure 3 ). The biological half-life (tA) was calculated from the plasma curve. Since some of the urine collections were incomplete, adequate total body curves could not be obtained for many subjects. Therefore Matthews' method, which uses only plasma radioactivity measurements, was employed to further analyze the data (13) . This method assumes that a) all catabolism occurs in the intravascular pool,3 b) any new protein synthesized is added only to the intravascular compartment, and c) rates of breakdown and rates of transfer of pro-tein between intravascular and extravascular compartments are constant.
We were able to analyze our data using a model system with one extravascular pool. Matthews' equations describing this system are as follows: K12 (fractional catabolic rate or fraction of total intravascular IgD catabolized per day) = The total quantity of IgD catabolized per day was calculated from the total intravascular IgD and the fractional catabolic rate constant, K,2, assuming that all catabolism occurs in the intravascular compartment. With the further assumption of a steady state, this is equivalent to the synthetic rate. Turnover rate (milligrams per kilogram per day) = total intravascular IgD (milligrams) X K12/body weight (kilograms).
Total serum proteins were determined by the biuret method. Serum paper electrophoresis was also performed. Serum immunoglobulin levels were determined by the antibody-in-agar method (2, 10). Serum IgD was estimated by the same method employing rabbit anti-IgD myeloma protein antisera from three different pools. The antisera used for analysis of subjects receiving preparations 1 and 2-b could detect IgD concentrations of greater than 0.003 and 0.008 mg per ml, respectively, whereas the antiserum used for preparation no. 2-a could detect IgD concentrations of greater than 0.017 mg per ml. Sera were analyzed for IgD content at various times in a single study and found to vary less than 10%o from the mean for that subject. Thus, the assumption of the steady state seemed realistic. The data were analyzed for significant correlations using Spearman's rank-order correlation coefficient method corrected for ties (15 labeled IgD (Table II) . Six patients (C.H., G.C., A.Ho., F.M., J.B., and O.K.) received two preparations (no. 1 and 2-a). In these patients the mean biological half-life was 82 hours for preparation 1 and 55 hours for preparation 2-a. The mean fractional catabolic rates were 0.33 and 0.48, respectively. The reasons for this discrepancy are unclear but may reflect a difference in metabolism between a myeloma IgD protein (preparation 2-a) and a nonmyeloma IgD protein (preparation 1). These results could also be explained by the minor contamination of preparation no. 1 with radioiodine-labeled low molecular weight IgM, which may have a longer half-life if it is metabolized like 18 S IgM (7). Analysis of the urine or whole body radioactivity in all patients given both preparations revealed no evidence of a significant amount of early degradable, i.e., denatured, labeled IgD. Despite these differences in behavior in six patients, the full range of values obtained with both preparations overlapped extensively for each parameter of metabolism studied (Table III) . The results for each preparation will be discussed separately.
IgD preparation no. 1. This 125I-labeled protein was given to 16 subjects. The fractional catabolic rates (about 3-fold) compared to the wide range of synthetic rates (about 50-fold), however, indicates that the latter plays the major role in determining IgD serum concentration.
Two patients with myotonic dystrophy (W.J., J.C.) were studied previously (12) IgD preparation no. 2. This preparation was iodinated in two lots, one with 1251 (preparation 2-a), the other with 131I (preparation 2-b). Since these two lots behaved similarly, they shall be discussed as one with the exception that patient B.M. (D myeloma, the source of preparation 2) will be considered separately.
Excluding patient B.M., 17 patients received preparation no. 2, six of whom had previously received preparation 1. Between 68 and 81%o of the injected radioiodinated IgD remained intravascular, with a median of 73%o. Serum 1gD levels varied within the wide range of normals previously reported. The range was from < 0.008 mg per ml to 0.080 mg per ml. Total body IgD varied from < 0.618 to 3.45 mg per kg.
IgD turnover rates ranged from < 0.147 to 1.13 mg per kg per day. Figure 4 demonstrates the strong positive correlation between serum IgD concentration and synthetic (turnover) rate for this preparation.
The biological half-life ranged from 46 hours to 78 hours. The fractional catabolic rate varied from 0.34 to 0.60 with a median value of 0.45. Serum concentration and fractional catabolic rate did not correlate significantly (correlation coefficient of -0.24, p > 0.10) ( Figure 5 ). If subject B.M. is included, a possibly significant correlation is found (r = -0.36, 0.10 > p > 0.05), but, like preparation no. 1, serum concentration (10-fold range) depended mainly on synthetic rate (8-fold range). No other parameters correlated well with biological half-life, fractional catabolic rate, or synthetic rate.
Patient B.M. had clinical and laboratory evidence of multiple myeloma and was producing an IgD myeloma protein, Type L. This protein was isolated and labeled with 131J and given back to the patient (preparation 2-b). Since this was the only study of the behavior of an autologous protein, it deserves special consideration. The serum IgD level (8.6 mg per ml) was the highest of any of the 28 subjects in this study. The biological half-life was 160 hours, the longest of any patient studied. The fractional catabolic rate (0.16) was the smallest of the entire series. As expected, the turnover rate was very high, 64 mg per kg per day, which in this 73-kg man amounted to 4.7 g per day. The median turnover rate for all other subjects was 0.396 mg per kg per day or about 0.028 g per day for a 70-kg man. Sixtyfive per cent of the labeled protein remained intravascular, which agrees with data from the other 27 subjects of this study. Thus this subject's high serum level was the result of two factors: a) a greatly increased synthetic rate, and b) a lower fractional catabolic rate.
Discussion
The present studies show important differences between the metabolism of IgD and the other Table IV . IgD has the lowest serum concentration of any of the immunoglobulins. The median value of all patients investigated in this present study was 0.023 mg per ml. This value is lower than the median value of 0.030 mg per ml for normal adults (2), due to inclusion in the present study of a large number of patients with multiple myeloma or macroglobulinemia who had low IgD levels. The serum level of IgD directly reflected the rate of IgD synthesis (Figure 4) The immunoglobulins are catabolized in a compartment in rapid equilibrium with the intravascular pool (16) . Thus, rates of catabolism can be meaningfully compared when expressed as the fraction of the intravascular pool catabolized each day. The median fractional catabolic rate for IgD was found to be 0.37. The fractional catabolic rates of IgG (median 0.07) and IgM (median 0.18) are notably lower (3, 7) . Certainly the catabolism of IgG (and IgM) is different from IgD.
The fractional catabolic rate of IgD (median 0.37) is closer to the median IgA fractional catabolic rates of 0.24 noted by Strober and his colleagues (6) and 0.37 reported by Solomon and Tomasi (5) . The ranges of observed fractional catabolic rates were 0.18 to 0.60 for IgD and 0.14 to 0.34 for IgA (6 (3) and in the mouse (19) . Subjects with high serum IgG concentrations due to myeloma, chronic infection, or hyperimmunization have increased rates of IgG catabolism (3, (19) (20) (21) (22) (23) , and those with hypogammaglobulinemia have decreased rates of catabolism (3, 24) . These catabolic adjustments to serum concentration constitute an IgG homeostatic regulatory mechanism. On the other hand, the serum levels of IgA and IgM do not influence their respective rates of catabolism. In contrast to the observations with these other classes of immunoglobulins, a significant negative correlation was observed between IgD fractional catabolic rate and serum concentration for preparation no. 1 and possibly for preparation no. 2 ( Figure 5 ), that is, those patients with the higher serum levels 'had the lower fractional catabolic rates. A similar negative correlation between these two parameters has been demonstrated for transferrin (25) and haptoglobin (26) in man. The correlation of serum albumin level and fractional catabolic rate is unclear, a negative correlative having been found in the rabbit (27) , a positive correla-tion in man (28, 29) . It must be emphasized, however, that we have been unable to study variations of fractional catabolic rate with changing IgD serum levels in the individual subject and that further study is necessary to confirm the fractional catabolic rate-serum concentration relationship. It is possible that serum IgD concentration and fractional catabolic rates are not causally related and that this apparent relationship may reflect only their mutual relationship to one or more still unknown factors.
IgD was distributed between intravascular and extravascular compartments differently from other immunoglobulin classes with similar ultracentrifugal sedimentation coefficients. About 75% of the total IgD (7.0 S) was found in the intravascular space after equilibration. In contrast, only about 40 to 50%o of IgG (6.6 S) and IgA (7-13 S) are intravascular (3) (4) (5) (6) . Smaller molecules such as albumin (4 S) and transferrin (5 S) behave like IgG and IgA (25, 30) . On the other hand, large molecules like IgM (18 S) and fibrinogen are similar to IgD in being about 70 to 80%o intravascular (7, 20) . The size and shape of radioiodinated IgD are the same as native IgD as shown by Sephadex gel filtration so that the purified, labeled protein used in these experiments is presumed to reflect the behavior of native IgD. Pre The median rate of IgD synthesis was 0.4 mg per kg per day. This is about 1 to 2% of the synthetic rates for IgG and IgA (and about 10%o of the IgM synthetic rate).
The median serum level of IgD (0.023 mg per ml in 27 subjects studied) was only about 0.2% of the median IgG level. The difference between relative serum levels (1: 465) and synthetic rates (1: 100) for IgD: IgG reflects the more rapid rate of IgD catabolism.
The biologic half-life of IgD is shorter than that of other immunoglobulins. The median half-life for IgD was 2.8 days. This contrasts with the t4 of IgM (5 days), IgA (6 days), and IgG (23 days). The fractional rates of catabolism of intravascular IgD (0.37) and IgA, however, are similar. The other immunoglobulins are catabolized at slower rates.
Studies in three patients with disordered metabolism of IgA or IgG revealed normal IgD metabolism, indicating that IgD is metabolized independently from IgA or IgG.
The fractional catabolic rate of IgD appears to be altered by the serum IgD concentration. Those subjects with high serum IgD levels tend to have relatively low fractional catabolic rates. This concentration-catabolism relationship for IgD is the opposite of that noted for IgG, where high serum levels are associated with relatively rapid IgG catabolism.
IgD is largely (73%) in the intravascular compartment. This contrasts with other 7 S immunoglobulins, for only 40 to 50% of the total body IgG and IgA is in the intravascular compartment. 
